Kathleen Colson

Statistics

Publications

Citations

836

H-Index

Active since

2004

Affiliations

Dana-Farber Cancer Institute(Current)

Harvard University

Massachusetts General Hospital

Millennium Engineering and Integration (United States)

Emory University

Kathleen Colson is an author at Dana-Farber Cancer Institute specializing in multiple myeloma therapy, multiple myeloma treatment, and multiple myeloma.

Publications per year

2004–2021

Publications

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

Paul G. Richardson, Constantine Mitsiades, Kathleen Colson et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2008 · 191 citations

Pharmacy, Pharmacology, Pharmacotherapy +15

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

Paul G. Richardson, Wanling Xie, Sundar Jagannath et al. · Blood · 2014 · 183 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial

Paul G. Richardson, J. Wolf, Andrzej Jakubowiak et al. · Journal of Clinical Oncology · 2011 · 119 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Phase II Trial of Single Agent Bortezomib (VELCADE®) in Patients with Previously Untreated Multiple Myeloma (MM).

Paul G. Richardson, Asher Chanan‐Khan, Robert Schlossman et al. · Blood · 2004 · 57 citations

Medicine, Pharmacology, Pharmacotherapy +11

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study.

Paul G. Richardson, Sundar Jagannath, Andrzej Jakubowiak et al. · Blood · 2008 · 42 citations

Medicine, Hematology, Pharmacotherapy +17

1–5 of 18